-
6 days ago | 
sensible-med.com | John Mandrola
The CHALLENGE trial tested cancer outcomes from a structured exercise program. NEJM published the study, more than a 100 news sites covered it, and hundreds reposted it on social media. So you know the results were positive. Hugely positive, in fact. And who, I ask, does not love the story that exercise vanquishes cancer? Sensible Medicine is a place to get the real story. This is a classic case when you have to let go of your love of great stories to see the details.
-
1 week ago | 
sensible-med.com | Adam Cifu
I did my residency at Beth Israel Hospital in Boston. Some people think of it as The House of God, I think of it as the home of Open Notes. Dr. Tom Delbanco was the chief of General Internal Medicine while I was there and was already advocating that patients have access to their medical records. He encouraged me to document clinic visits in notes that I’d be comfortable with my patients reading.
-
1 week ago | 
sensible-med.com | Vinay Prasad |Adam Cifu |John Mandrola
The most common question we get asked is: is there a course on how to become better at critically reading medical research. Here it is!This is the third of 9 videos that we recorded as part of a course on clinical appraisal, and there will be many more to come. This and future videos will be made available as a thank you to paid subscribers.
-
1 week ago | 
sensible-med.com | Adam Cifu |John Mandrola
Yup, it’s a little goofy but we have Merch. Just t-shirts but they’re actually kind of cool. You can see VP modeling one in this video. The link to the shop is here.
-
2 weeks ago | 
sensible-med.com | Adam Cifu
When I joined Vinay Prasad, , Marty Makary, and Zubin Demania to launch Sensible Medicine as a shared Substack in the summer of 2022, I would not have guessed I’d eventually be writing about decisions two of those doctors would be making at the FDA. As John and I wrote a couple of weeks ago, we are excited to see what Vinay will do as the Director of the Center for Biologics Evaluation and Research at the FDA.
-
2 weeks ago | 
sensible-med.com | John Mandrola
Do read Adam Cifu’s column this morning on the new leadership at FDA. Yesterday’s NEJM article by Prasad and Makary was excellent. It’s rational, calm, and their call for evidence is welcome. Always remember: established makers of drugs and devices overflow with funds. They can and will fund trials—if required. I attach the Town Hall video posted yesterday. It’s excellent. As always, when Vinay lectures, it is a tour de force of critical appraisal.
-
2 weeks ago | 
sensible-med.com | John Mandrola
The BedMed trial, published in JAMA this month, looks like a regular randomized controlled trial (RCT). One group of patients with high blood pressure took their meds in the morning, the other took the same meds at night. Major adverse cardiac events (MACE) were not different. The Canadian investigators randomized more than 3500 patients and followed them for nearly 5 years. I don’t know how much money and time were spent on the trial, but it was a lot.
-
3 weeks ago | 
sensible-med.com | Vinay Prasad |Adam Cifu |John Mandrola
This is a long one! 83 minutes. This is the second podcast in which we answer questions from a our “ask us anything” post. We recorded this one before our most recent podcast — kind of like Abbey Road and Let it Be — so we were still graced by Vinay’s presence. In fact, we recorded it in his studio. We still have about a half dozen questions to answer; we will cover those on an upcoming podcast. Enjoy.
-
3 weeks ago | 
sensible-med.com | Adam Cifu
Following up with another 35 “diseases just learned.” Please look back to last week’s intro if you are just coming to this series. Like Part I, this is a gift to our paid subscribers.
-
3 weeks ago | 
sensible-med.com | Vinay Prasad |Adam Cifu |John Mandrola
The most common question we get asked is: is there a course on how to become better at critically reading medical research. Here it is!This is the second of 9 videos that we recorded as part of a course on clinical appraisal, and there will be many more to come. This and future videos will be made available as a thank you to paid subscribers.